Hexarelin
Examorelin / HEX
Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.
Mécanisme d'action
Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection. GH response attenuates after 4-8 weeks (tachyphylaxis). Often cycled 8 weeks on, 4 weeks off.
Notes de recherche
Clinical Research Status
Hexarelin has been studied in multiple Phase 1/2 clinical trials for growth hormone deficiency, cardiac function, and aging-related decline, but has not progressed to regulatory approval. Italian cardiovascular research groups have published extensively on its direct cardiac effects independent of GH release. It remains available primarily as a research chemical, with clinical interest continuing in growth hormone secretagogue pharmacology and cardioprotection.
Key Published Findings
Studies demonstrate hexarelin produces the largest GH release among GHRPs, with peak GH levels of 30-50 ng/mL in healthy subjects after a single subcutaneous dose. Cardiovascular research shows hexarelin directly binds cardiac receptors (CD36), reducing cardiac fibrosis and improving ventricular function independent of GH/IGF-1 signaling. However, hexarelin shows significant tachyphylaxis with continuous use, with GH response diminishing substantially after 4-8 weeks of daily administration.
Safety Profile
Short-term studies show hexarelin is well-tolerated with common effects including transient hunger increase, flushing, and mild water retention consistent with GH elevation. The pronounced cortisol and prolactin co-stimulation distinguishes hexarelin from more selective GHRPs like ipamorelin. Tachyphylaxis (reduced response over time) limits its practical utility for sustained GH elevation, though pulsatile or intermittent protocols may partially mitigate this.
Comparison to Related Compounds
Hexarelin produces stronger GH release than GHRP-6 or GHRP-2 but with greater cortisol and prolactin stimulation, making it less selective. Compared to ipamorelin, which is highly GH-specific, hexarelin's broader receptor activation produces additional cardiovascular effects but more side effects. Unlike GHRH analogs (CJC-1295, sermorelin), hexarelin works through the ghrelin receptor pathway and can synergize with GHRH for amplified GH release.
Community Observations
Researchers note that hexarelin's rapid tachyphylaxis makes it poorly suited for continuous long-term GH elevation protocols. Its unique cardioprotective properties have generated interest separate from GH-releasing applications, particularly for post-myocardial infarction recovery research. Some protocols use hexarelin in short cycles (2-4 weeks) or intermittently to maximize GH response before tachyphylaxis develops.
Moitié de vie
~1 hour
Réconstitution
Bacteriostatic water (BAC)
Conservation
Lyophilisé
Refrigerate 2-8C up to 18 months.
Réconstitué
Refrigerate 2-8C. Use within 14 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que Hexarelin ?
Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.
Comment agit Hexarelin ?
Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.
Quel est le statut réglementaire de Hexarelin aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de Hexarelin ?
~1 hour
Sous quels autres noms Hexarelin est-il connu ?
Examorelin, HEX
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète